temozolomide has been researched along with Cancer of Colon in 21 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Using this approach, we have been able to monitor caspase-3 activation and subsequent apoptosis induction after camptothecin and temozolomide treatment on xenograft mouse models of colon cancer and glioblastoma, respectively." | 3.77 | In vivo imaging of early stage apoptosis by measuring real-time caspase-3/7 activation. ( Cappella, P; Pesenti, E; Rizzitano, S; Scabini, M; Stellari, F; Texido, G, 2011) |
| " These studies evaluated the antitumor efficacy of CEP-7055 using orthotopic models of glioblastoma and colon carcinoma in combination with temozolomide, and irinotecan and oxaliplatin, respectively, for their effects on primary and metastatic tumor burden and median survival." | 3.73 | The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice. ( Hunter, K; Jones-Bolin, S; Klein-Szanto, A; Ruggeri, B; Zhao, H, 2006) |
| " The biological effects of two novel PARP inhibitors, NU1025 (8-hydroxy-2-methylquinazolin-4-[3H]one, Ki = 48 nM) and NU1085 [2-(4-hydroxyphenyl)benzamidazole-4-carboxamide, Ki = 6 nM], in combination with temozolomide (TM) or topotecan (TP) have been studied in 12 human tumor cell lines (lung, colon, ovary, and breast cancer)." | 3.70 | Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. ( Calvert, AH; Curtin, NJ; Delaney, CA; Durkacz, BW; Hostomsky, Z; Kyle, S; Newell, DR; Wang, LZ; White, AW, 2000) |
| "The in vitro cytotoxicity of 8-carbamoyl-3-methylimidazo [5,1-d]-1,2,3,5-tetrazine-4(3H)-one (temozolomide) with concurrent X-irradiation was examined in a human glioblastoma cell line (U373MG) as a potential radio-chemotherapeutic treatment for malignant glioma." | 3.69 | In vitro evaluation of temozolomide combined with X-irradiation. ( Glaser, MG; Marcus, K; Newlands, ES; Porteous, JK; Wedge, SR, 1997) |
| "Three human colon cancer cell lines were used, SW480 cells, which are wild-type for mismatch repair genes and have mutated p53, HCT116 cells, which are mutant in hMLH1 and wild-type for p53, and HCT15 cells, which are mutant in hMSH6 and mutant in p53 as well." | 1.31 | Base excision repair as a therapeutic target in colon cancer. ( Gerson, SL; Liu, L; Nakatsuru, Y, 2002) |
| "Human colon cancer (HT29) cell survival was decreased by almost 1 log when treated with 500 microM temozolomide prior to 150 microM BCNU." | 1.29 | Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. ( Dolan, ME; Mitchell, RB, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 6 (28.57) | 18.2507 |
| 2000's | 8 (38.10) | 29.6817 |
| 2010's | 2 (9.52) | 24.3611 |
| 2020's | 4 (19.05) | 2.80 |
| Authors | Studies |
|---|---|
| Morano, F | 1 |
| Raimondi, A | 1 |
| Pagani, F | 1 |
| Lonardi, S | 1 |
| Salvatore, L | 1 |
| Cremolini, C | 1 |
| Murgioni, S | 1 |
| Randon, G | 1 |
| Palermo, F | 1 |
| Antonuzzo, L | 1 |
| Pella, N | 1 |
| Racca, P | 1 |
| Prisciandaro, M | 1 |
| Niger, M | 1 |
| Corti, F | 1 |
| Bergamo, F | 1 |
| Zaniboni, A | 1 |
| Ratti, M | 1 |
| Palazzo, M | 1 |
| Cagnazzo, C | 1 |
| Calegari, MA | 1 |
| Marmorino, F | 1 |
| Capone, I | 1 |
| Conca, E | 1 |
| Busico, A | 1 |
| Brich, S | 1 |
| Tamborini, E | 1 |
| Perrone, F | 1 |
| Di Maio, M | 1 |
| Milione, M | 1 |
| Di Bartolomeo, M | 1 |
| de Braud, F | 1 |
| Pietrantonio, F | 1 |
| Almoshari, Y | 1 |
| Iqbal, H | 1 |
| Razzaq, A | 1 |
| Ali Ahmad, K | 1 |
| Khan, MK | 1 |
| Saeed Alqahtani, S | 1 |
| Hadi Sultan, M | 1 |
| Ali Khan, B | 1 |
| Shaw, R | 1 |
| Karmakar, S | 1 |
| Basu, M | 1 |
| Ghosh, MK | 1 |
| Kobayashi, N | 1 |
| Takeda, Y | 1 |
| Okubo, N | 1 |
| Suzuki, A | 1 |
| Tokuhisa, M | 1 |
| Hiroshima, Y | 1 |
| Ichikawa, Y | 1 |
| Bocangel, D | 1 |
| Sengupta, S | 1 |
| Mitra, S | 1 |
| Bhakat, KK | 1 |
| Jaiswal, AS | 1 |
| Banerjee, S | 1 |
| Panda, H | 1 |
| Bulkin, CD | 1 |
| Izumi, T | 1 |
| Sarkar, FH | 1 |
| Ostrov, DA | 1 |
| Narayan, S | 1 |
| Scabini, M | 1 |
| Stellari, F | 1 |
| Cappella, P | 1 |
| Rizzitano, S | 1 |
| Texido, G | 1 |
| Pesenti, E | 1 |
| Mayes, PA | 1 |
| Degenhardt, YY | 1 |
| Wood, A | 1 |
| Toporovskya, Y | 1 |
| Diskin, SJ | 1 |
| Haglund, E | 1 |
| Moy, C | 1 |
| Wooster, R | 1 |
| Maris, JM | 1 |
| Liu, L | 5 |
| Nakatsuru, Y | 1 |
| Gerson, SL | 5 |
| Tentori, L | 1 |
| Leonetti, C | 1 |
| Scarsella, M | 1 |
| Muzi, A | 1 |
| Mazzon, E | 1 |
| Vergati, M | 1 |
| Forini, O | 1 |
| Lapidus, R | 1 |
| Xu, W | 1 |
| Dorio, AS | 1 |
| Zhang, J | 1 |
| Cuzzocrea, S | 1 |
| Graziani, G | 1 |
| Jones-Bolin, S | 1 |
| Zhao, H | 1 |
| Hunter, K | 1 |
| Klein-Szanto, A | 1 |
| Ruggeri, B | 1 |
| Mitchell, RB | 1 |
| Dolan, ME | 1 |
| Markowitz, S | 1 |
| Wedge, SR | 1 |
| Porteous, JK | 1 |
| Glaser, MG | 1 |
| Marcus, K | 1 |
| Newlands, ES | 1 |
| Reese, JS | 1 |
| Davis, BM | 1 |
| Taverna, P | 2 |
| Whitacre, CM | 1 |
| Chatterjee, S | 1 |
| Delaney, CA | 1 |
| Wang, LZ | 1 |
| Kyle, S | 1 |
| White, AW | 1 |
| Calvert, AH | 1 |
| Curtin, NJ | 1 |
| Durkacz, BW | 1 |
| Hostomsky, Z | 1 |
| Newell, DR | 1 |
| Plumb, JA | 1 |
| Strathdee, G | 1 |
| Sludden, J | 1 |
| Kaye, SB | 1 |
| Brown, R | 1 |
| Hwang, HS | 1 |
| Hanson, AJ | 1 |
| Kinsella, TJ | 1 |
| Deans, B | 1 |
| Tisdale, MJ | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study[NCT03832621] | Phase 2 | 135 participants (Actual) | Interventional | 2019-03-25 | Completed | ||
| A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas[NCT01851369] | Phase 1/Phase 2 | 93 participants (Actual) | Interventional | 2013-07-12 | Completed | ||
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| Randomized Phase II Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.[NCT03467178] | Phase 2 | 119 participants (Anticipated) | Interventional | 2018-07-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for temozolomide and Cancer of Colon
| Article | Year |
|---|---|
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Humans; Ipi | 2022 |
Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carc | 2021 |
19 other studies available for temozolomide and Cancer of Colon
| Article | Year |
|---|---|
Development of nanocubosomes co-loaded with dual anticancer agents curcumin and temozolomide for effective Colon cancer therapy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Curcumin; Drug Carriers; Drug Liberation | 2022 |
DDX5 (p68) orchestrates β-catenin, RelA and SP1 mediated MGMT gene expression in human colon cancer cells: Implication in TMZ chemoresistance.
Topics: Alkylating Agents; beta Catenin; Cell Line, Tumor; Colonic Neoplasms; DNA Modification Methylases; D | 2023 |
p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor.
Topics: Antineoplastic Agents, Alkylating; Colonic Neoplasms; Consensus Sequence; Dacarbazine; DNA Repair; D | 2009 |
A novel inhibitor of DNA polymerase beta enhances the ability of temozolomide to impair the growth of colon cancer cells.
Topics: Adenomatous Polyposis Coli Protein; Animals; Antineoplastic Agents; Binding Sites; Cell Death; Cell | 2009 |
In vivo imaging of early stage apoptosis by measuring real-time caspase-3/7 activation.
Topics: Animals; Apoptosis; Blotting, Western; Camptothecin; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Pr | 2011 |
Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocy | 2013 |
Base excision repair as a therapeutic target in colon cancer.
Topics: Animals; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Bone Marrow Diseases; Chromosome Abe | 2002 |
Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Proliferation; Colonic Neoplasms; | 2006 |
The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbazo | 2006 |
Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colonic Neoplasms; Dacarbazine; | 1993 |
Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Colonic Neoplasms; Dacarbazine; DNA Adducts; DNA Dama | 1996 |
In vitro evaluation of temozolomide combined with X-irradiation.
Topics: Adenocarcinoma; Antineoplastic Agents, Alkylating; Brain Neoplasms; Colonic Neoplasms; Combined Moda | 1997 |
Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carmustine; Colonic Neoplasms; Da | 1999 |
Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle; Colonic Neoplasms; Dacarbazine; DNA Repai | 1999 |
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Survival; Colonic Neoplasms; Dacarbazin | 2000 |
Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agent | 2000 |
Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells.
Topics: Apoptosis; Blotting, Western; Colonic Neoplasms; Dacarbazine; DNA Damage; DNA Repair; DNA, Neoplasm; | 2001 |
Antitumour imidazotetrazines XXVIII 3-methyladenine DNA glycosylase activity in cell lines sensitive and resistant to temozolomide.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Burkitt Lymphoma; Cell Line; Cell Survival; Chromato | 1992 |
Antitumor imidazotetrazines--XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line; Chlorambucil; Colonic Neoplasms; Dacarbaz | 1987 |